DIABETOL METAB SYNDR 润色咨询

Diabetology & Metabolic Syndrome

出版年份：2009 年文章数：898 投稿命中率： 开通期刊会员，数据随心看

出版周期：Irregular 自引率：1.9% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2269098, encodeId=ab4c22690984a, content=审稿速度:12.0 | 投稿命中率:75.0<br>偏重的研究方向：心衰和代谢<br>经验分享：投稿一共经历了10个月才接受，中间第一次审稿只找到一个审稿人，八个月才给意见，小修后又找了一个审稿人，再次小修，最后接收，一开始都不抱希望了，最后结果还是好的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c026408695, createdName=ms1000000018536500, createdTime=Thu Jun 12 22:19:31 CST 2025, time=2025-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2248527, encodeId=f623224852e05, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享：2024年7月投稿，到今天才给我1个审稿人的意见。中间催了3次啊，受不了了。重点是这个审稿人只是总结了我的文章，只提优点，没说缺点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0602318384, createdName=vgirlxin, createdTime=Fri Jan 17 20:29:55 CST 2025, time=2025-01-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：炎症;糖尿病;冠心病<br>经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2232367, encodeId=4c9f223236ebb, content=审稿速度:12.0 | 投稿命中率:50.0<br>偏重的研究方向：代谢综合征;糖尿病<br>经验分享：10月9号分配编辑，10月22依然Editor assigned，生死未卜, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1139312269, createdName=ms7000000399929724, createdTime=Tue Oct 22 10:48:41 CST 2024, time=2024-10-22, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2240719, encodeId=61512240e19e1, content=该期刊比较欢迎与糖尿病和代谢综合征相关的原创研究论文、综述、评论文章等<br>主要涵盖糖尿病及其相关代谢综合征的研究，包括临床研究、综述、评论等。因此，确保你的研究主题与该期刊的宗旨一致是非常重要的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822132, createdTime=Tue Dec 03 23:37:32 CST 2024, time=2024-12-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2216387, encodeId=cbd4221638eb4, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向：糖尿病<br>经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。<br><br>Submission status Date<br>Submission received<br>25 Apr 2024<br>Technical check<br>Submission status Date<br>Submission is under technical check<br>25 Apr 2024<br>Submission passed technical check<br>26 Apr 2024<br>Editorial assignment<br>Submission status Date<br>Ready for editorial assignment<br>26 Apr 2024<br>With editor<br>Submission status Date<br>Editor assigned<br>26 Apr 2024<br>Peer review<br>Submission status Date<br>Submission under peer review<br>07 May 2024<br>Revision requested<br>18 Jun 2024<br>Revision received<br>26 Jun 2024<br>Submission passed technical check<br>27 Jun 2024<br>Submission accepted<br>Submission status Date<br>Submission accepted<br>18 Jul 2024<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>22 Jul 2024<br>Production<br>Submission status Date<br>Publishing and rights complete<br>23 Jul 2024<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf06405121, createdName=ms4000000387006148, createdTime=Tue Jul 23 09:56:04 CST 2024, time=2024-07-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向：糖尿病心肌病;药物治疗<br>经验分享：3.19投稿<br>4.14接收<br>5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京)]
    2025-06-12 ms1000000018536500 来自北京

    审稿速度:12.0 | 投稿命中率:75.0
    偏重的研究方向：心衰和代谢
    经验分享：投稿一共经历了10个月才接受，中间第一次审稿只找到一个审稿人，八个月才给意见，小修后又找了一个审稿人，再次小修，最后接收，一开始都不抱希望了，最后结果还是好的

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2269098, encodeId=ab4c22690984a, content=审稿速度:12.0 | 投稿命中率:75.0<br>偏重的研究方向：心衰和代谢<br>经验分享：投稿一共经历了10个月才接受，中间第一次审稿只找到一个审稿人，八个月才给意见，小修后又找了一个审稿人，再次小修，最后接收，一开始都不抱希望了，最后结果还是好的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c026408695, createdName=ms1000000018536500, createdTime=Thu Jun 12 22:19:31 CST 2025, time=2025-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2248527, encodeId=f623224852e05, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享：2024年7月投稿，到今天才给我1个审稿人的意见。中间催了3次啊，受不了了。重点是这个审稿人只是总结了我的文章，只提优点，没说缺点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0602318384, createdName=vgirlxin, createdTime=Fri Jan 17 20:29:55 CST 2025, time=2025-01-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：炎症;糖尿病;冠心病<br>经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2232367, encodeId=4c9f223236ebb, content=审稿速度:12.0 | 投稿命中率:50.0<br>偏重的研究方向：代谢综合征;糖尿病<br>经验分享：10月9号分配编辑，10月22依然Editor assigned，生死未卜, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1139312269, createdName=ms7000000399929724, createdTime=Tue Oct 22 10:48:41 CST 2024, time=2024-10-22, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2240719, encodeId=61512240e19e1, content=该期刊比较欢迎与糖尿病和代谢综合征相关的原创研究论文、综述、评论文章等<br>主要涵盖糖尿病及其相关代谢综合征的研究，包括临床研究、综述、评论等。因此，确保你的研究主题与该期刊的宗旨一致是非常重要的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822132, createdTime=Tue Dec 03 23:37:32 CST 2024, time=2024-12-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2216387, encodeId=cbd4221638eb4, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向：糖尿病<br>经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。<br><br>Submission status Date<br>Submission received<br>25 Apr 2024<br>Technical check<br>Submission status Date<br>Submission is under technical check<br>25 Apr 2024<br>Submission passed technical check<br>26 Apr 2024<br>Editorial assignment<br>Submission status Date<br>Ready for editorial assignment<br>26 Apr 2024<br>With editor<br>Submission status Date<br>Editor assigned<br>26 Apr 2024<br>Peer review<br>Submission status Date<br>Submission under peer review<br>07 May 2024<br>Revision requested<br>18 Jun 2024<br>Revision received<br>26 Jun 2024<br>Submission passed technical check<br>27 Jun 2024<br>Submission accepted<br>Submission status Date<br>Submission accepted<br>18 Jul 2024<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>22 Jul 2024<br>Production<br>Submission status Date<br>Publishing and rights complete<br>23 Jul 2024<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf06405121, createdName=ms4000000387006148, createdTime=Tue Jul 23 09:56:04 CST 2024, time=2024-07-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向：糖尿病心肌病;药物治疗<br>经验分享：3.19投稿<br>4.14接收<br>5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京)]
    2025-01-17 vgirlxin 来自湖北省

    审稿速度:12.0 | 投稿命中率:50.0
    经验分享：2024年7月投稿，到今天才给我1个审稿人的意见。中间催了3次啊，受不了了。重点是这个审稿人只是总结了我的文章，只提优点，没说缺点。

    3

    展开3条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2269098, encodeId=ab4c22690984a, content=审稿速度:12.0 | 投稿命中率:75.0<br>偏重的研究方向：心衰和代谢<br>经验分享：投稿一共经历了10个月才接受，中间第一次审稿只找到一个审稿人，八个月才给意见，小修后又找了一个审稿人，再次小修，最后接收，一开始都不抱希望了，最后结果还是好的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c026408695, createdName=ms1000000018536500, createdTime=Thu Jun 12 22:19:31 CST 2025, time=2025-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2248527, encodeId=f623224852e05, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享：2024年7月投稿，到今天才给我1个审稿人的意见。中间催了3次啊，受不了了。重点是这个审稿人只是总结了我的文章，只提优点，没说缺点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0602318384, createdName=vgirlxin, createdTime=Fri Jan 17 20:29:55 CST 2025, time=2025-01-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：炎症;糖尿病;冠心病<br>经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2232367, encodeId=4c9f223236ebb, content=审稿速度:12.0 | 投稿命中率:50.0<br>偏重的研究方向：代谢综合征;糖尿病<br>经验分享：10月9号分配编辑，10月22依然Editor assigned，生死未卜, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1139312269, createdName=ms7000000399929724, createdTime=Tue Oct 22 10:48:41 CST 2024, time=2024-10-22, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2240719, encodeId=61512240e19e1, content=该期刊比较欢迎与糖尿病和代谢综合征相关的原创研究论文、综述、评论文章等<br>主要涵盖糖尿病及其相关代谢综合征的研究，包括临床研究、综述、评论等。因此，确保你的研究主题与该期刊的宗旨一致是非常重要的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822132, createdTime=Tue Dec 03 23:37:32 CST 2024, time=2024-12-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2216387, encodeId=cbd4221638eb4, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向：糖尿病<br>经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。<br><br>Submission status Date<br>Submission received<br>25 Apr 2024<br>Technical check<br>Submission status Date<br>Submission is under technical check<br>25 Apr 2024<br>Submission passed technical check<br>26 Apr 2024<br>Editorial assignment<br>Submission status Date<br>Ready for editorial assignment<br>26 Apr 2024<br>With editor<br>Submission status Date<br>Editor assigned<br>26 Apr 2024<br>Peer review<br>Submission status Date<br>Submission under peer review<br>07 May 2024<br>Revision requested<br>18 Jun 2024<br>Revision received<br>26 Jun 2024<br>Submission passed technical check<br>27 Jun 2024<br>Submission accepted<br>Submission status Date<br>Submission accepted<br>18 Jul 2024<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>22 Jul 2024<br>Production<br>Submission status Date<br>Publishing and rights complete<br>23 Jul 2024<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf06405121, createdName=ms4000000387006148, createdTime=Tue Jul 23 09:56:04 CST 2024, time=2024-07-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向：糖尿病心肌病;药物治疗<br>经验分享：3.19投稿<br>4.14接收<br>5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京)]
    2023-01-01 ms9000001742428006 来自广东省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向：炎症;糖尿病;冠心病
    经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！

    3

    展开3条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2269098, encodeId=ab4c22690984a, content=审稿速度:12.0 | 投稿命中率:75.0<br>偏重的研究方向：心衰和代谢<br>经验分享：投稿一共经历了10个月才接受，中间第一次审稿只找到一个审稿人，八个月才给意见，小修后又找了一个审稿人，再次小修，最后接收，一开始都不抱希望了，最后结果还是好的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c026408695, createdName=ms1000000018536500, createdTime=Thu Jun 12 22:19:31 CST 2025, time=2025-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2248527, encodeId=f623224852e05, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享：2024年7月投稿，到今天才给我1个审稿人的意见。中间催了3次啊，受不了了。重点是这个审稿人只是总结了我的文章，只提优点，没说缺点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0602318384, createdName=vgirlxin, createdTime=Fri Jan 17 20:29:55 CST 2025, time=2025-01-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：炎症;糖尿病;冠心病<br>经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2232367, encodeId=4c9f223236ebb, content=审稿速度:12.0 | 投稿命中率:50.0<br>偏重的研究方向：代谢综合征;糖尿病<br>经验分享：10月9号分配编辑，10月22依然Editor assigned，生死未卜, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1139312269, createdName=ms7000000399929724, createdTime=Tue Oct 22 10:48:41 CST 2024, time=2024-10-22, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2240719, encodeId=61512240e19e1, content=该期刊比较欢迎与糖尿病和代谢综合征相关的原创研究论文、综述、评论文章等<br>主要涵盖糖尿病及其相关代谢综合征的研究，包括临床研究、综述、评论等。因此，确保你的研究主题与该期刊的宗旨一致是非常重要的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822132, createdTime=Tue Dec 03 23:37:32 CST 2024, time=2024-12-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2216387, encodeId=cbd4221638eb4, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向：糖尿病<br>经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。<br><br>Submission status Date<br>Submission received<br>25 Apr 2024<br>Technical check<br>Submission status Date<br>Submission is under technical check<br>25 Apr 2024<br>Submission passed technical check<br>26 Apr 2024<br>Editorial assignment<br>Submission status Date<br>Ready for editorial assignment<br>26 Apr 2024<br>With editor<br>Submission status Date<br>Editor assigned<br>26 Apr 2024<br>Peer review<br>Submission status Date<br>Submission under peer review<br>07 May 2024<br>Revision requested<br>18 Jun 2024<br>Revision received<br>26 Jun 2024<br>Submission passed technical check<br>27 Jun 2024<br>Submission accepted<br>Submission status Date<br>Submission accepted<br>18 Jul 2024<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>22 Jul 2024<br>Production<br>Submission status Date<br>Publishing and rights complete<br>23 Jul 2024<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf06405121, createdName=ms4000000387006148, createdTime=Tue Jul 23 09:56:04 CST 2024, time=2024-07-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向：糖尿病心肌病;药物治疗<br>经验分享：3.19投稿<br>4.14接收<br>5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京)]
    2024-10-22 ms7000000399929724 来自山东省

    审稿速度:12.0 | 投稿命中率:50.0
    偏重的研究方向：代谢综合征;糖尿病
    经验分享：10月9号分配编辑，10月22依然Editor assigned，生死未卜

    13

    展开13条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2269098, encodeId=ab4c22690984a, content=审稿速度:12.0 | 投稿命中率:75.0<br>偏重的研究方向：心衰和代谢<br>经验分享：投稿一共经历了10个月才接受，中间第一次审稿只找到一个审稿人，八个月才给意见，小修后又找了一个审稿人，再次小修，最后接收，一开始都不抱希望了，最后结果还是好的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c026408695, createdName=ms1000000018536500, createdTime=Thu Jun 12 22:19:31 CST 2025, time=2025-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2248527, encodeId=f623224852e05, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享：2024年7月投稿，到今天才给我1个审稿人的意见。中间催了3次啊，受不了了。重点是这个审稿人只是总结了我的文章，只提优点，没说缺点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0602318384, createdName=vgirlxin, createdTime=Fri Jan 17 20:29:55 CST 2025, time=2025-01-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：炎症;糖尿病;冠心病<br>经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2232367, encodeId=4c9f223236ebb, content=审稿速度:12.0 | 投稿命中率:50.0<br>偏重的研究方向：代谢综合征;糖尿病<br>经验分享：10月9号分配编辑，10月22依然Editor assigned，生死未卜, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1139312269, createdName=ms7000000399929724, createdTime=Tue Oct 22 10:48:41 CST 2024, time=2024-10-22, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2240719, encodeId=61512240e19e1, content=该期刊比较欢迎与糖尿病和代谢综合征相关的原创研究论文、综述、评论文章等<br>主要涵盖糖尿病及其相关代谢综合征的研究，包括临床研究、综述、评论等。因此，确保你的研究主题与该期刊的宗旨一致是非常重要的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822132, createdTime=Tue Dec 03 23:37:32 CST 2024, time=2024-12-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2216387, encodeId=cbd4221638eb4, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向：糖尿病<br>经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。<br><br>Submission status Date<br>Submission received<br>25 Apr 2024<br>Technical check<br>Submission status Date<br>Submission is under technical check<br>25 Apr 2024<br>Submission passed technical check<br>26 Apr 2024<br>Editorial assignment<br>Submission status Date<br>Ready for editorial assignment<br>26 Apr 2024<br>With editor<br>Submission status Date<br>Editor assigned<br>26 Apr 2024<br>Peer review<br>Submission status Date<br>Submission under peer review<br>07 May 2024<br>Revision requested<br>18 Jun 2024<br>Revision received<br>26 Jun 2024<br>Submission passed technical check<br>27 Jun 2024<br>Submission accepted<br>Submission status Date<br>Submission accepted<br>18 Jul 2024<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>22 Jul 2024<br>Production<br>Submission status Date<br>Publishing and rights complete<br>23 Jul 2024<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf06405121, createdName=ms4000000387006148, createdTime=Tue Jul 23 09:56:04 CST 2024, time=2024-07-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向：糖尿病心肌病;药物治疗<br>经验分享：3.19投稿<br>4.14接收<br>5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京)]
    2023-09-26 ms4000001372213942 来自陕西省

    审稿速度:3.0 | 投稿命中率:50.0
    经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀

    7

    展开7条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2269098, encodeId=ab4c22690984a, content=审稿速度:12.0 | 投稿命中率:75.0<br>偏重的研究方向：心衰和代谢<br>经验分享：投稿一共经历了10个月才接受，中间第一次审稿只找到一个审稿人，八个月才给意见，小修后又找了一个审稿人，再次小修，最后接收，一开始都不抱希望了，最后结果还是好的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c026408695, createdName=ms1000000018536500, createdTime=Thu Jun 12 22:19:31 CST 2025, time=2025-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2248527, encodeId=f623224852e05, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享：2024年7月投稿，到今天才给我1个审稿人的意见。中间催了3次啊，受不了了。重点是这个审稿人只是总结了我的文章，只提优点，没说缺点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0602318384, createdName=vgirlxin, createdTime=Fri Jan 17 20:29:55 CST 2025, time=2025-01-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：炎症;糖尿病;冠心病<br>经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2232367, encodeId=4c9f223236ebb, content=审稿速度:12.0 | 投稿命中率:50.0<br>偏重的研究方向：代谢综合征;糖尿病<br>经验分享：10月9号分配编辑，10月22依然Editor assigned，生死未卜, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1139312269, createdName=ms7000000399929724, createdTime=Tue Oct 22 10:48:41 CST 2024, time=2024-10-22, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2240719, encodeId=61512240e19e1, content=该期刊比较欢迎与糖尿病和代谢综合征相关的原创研究论文、综述、评论文章等<br>主要涵盖糖尿病及其相关代谢综合征的研究，包括临床研究、综述、评论等。因此，确保你的研究主题与该期刊的宗旨一致是非常重要的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822132, createdTime=Tue Dec 03 23:37:32 CST 2024, time=2024-12-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2216387, encodeId=cbd4221638eb4, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向：糖尿病<br>经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。<br><br>Submission status Date<br>Submission received<br>25 Apr 2024<br>Technical check<br>Submission status Date<br>Submission is under technical check<br>25 Apr 2024<br>Submission passed technical check<br>26 Apr 2024<br>Editorial assignment<br>Submission status Date<br>Ready for editorial assignment<br>26 Apr 2024<br>With editor<br>Submission status Date<br>Editor assigned<br>26 Apr 2024<br>Peer review<br>Submission status Date<br>Submission under peer review<br>07 May 2024<br>Revision requested<br>18 Jun 2024<br>Revision received<br>26 Jun 2024<br>Submission passed technical check<br>27 Jun 2024<br>Submission accepted<br>Submission status Date<br>Submission accepted<br>18 Jul 2024<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>22 Jul 2024<br>Production<br>Submission status Date<br>Publishing and rights complete<br>23 Jul 2024<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf06405121, createdName=ms4000000387006148, createdTime=Tue Jul 23 09:56:04 CST 2024, time=2024-07-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向：糖尿病心肌病;药物治疗<br>经验分享：3.19投稿<br>4.14接收<br>5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京)]
    2024-12-03 ms3000001788822132 来自上海

    该期刊比较欢迎与糖尿病和代谢综合征相关的原创研究论文、综述、评论文章等
    主要涵盖糖尿病及其相关代谢综合征的研究，包括临床研究、综述、评论等。因此，确保你的研究主题与该期刊的宗旨一致是非常重要的。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2269098, encodeId=ab4c22690984a, content=审稿速度:12.0 | 投稿命中率:75.0<br>偏重的研究方向：心衰和代谢<br>经验分享：投稿一共经历了10个月才接受，中间第一次审稿只找到一个审稿人，八个月才给意见，小修后又找了一个审稿人，再次小修，最后接收，一开始都不抱希望了，最后结果还是好的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c026408695, createdName=ms1000000018536500, createdTime=Thu Jun 12 22:19:31 CST 2025, time=2025-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2248527, encodeId=f623224852e05, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享：2024年7月投稿，到今天才给我1个审稿人的意见。中间催了3次啊，受不了了。重点是这个审稿人只是总结了我的文章，只提优点，没说缺点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0602318384, createdName=vgirlxin, createdTime=Fri Jan 17 20:29:55 CST 2025, time=2025-01-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：炎症;糖尿病;冠心病<br>经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2232367, encodeId=4c9f223236ebb, content=审稿速度:12.0 | 投稿命中率:50.0<br>偏重的研究方向：代谢综合征;糖尿病<br>经验分享：10月9号分配编辑，10月22依然Editor assigned，生死未卜, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1139312269, createdName=ms7000000399929724, createdTime=Tue Oct 22 10:48:41 CST 2024, time=2024-10-22, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2240719, encodeId=61512240e19e1, content=该期刊比较欢迎与糖尿病和代谢综合征相关的原创研究论文、综述、评论文章等<br>主要涵盖糖尿病及其相关代谢综合征的研究，包括临床研究、综述、评论等。因此，确保你的研究主题与该期刊的宗旨一致是非常重要的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822132, createdTime=Tue Dec 03 23:37:32 CST 2024, time=2024-12-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2216387, encodeId=cbd4221638eb4, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向：糖尿病<br>经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。<br><br>Submission status Date<br>Submission received<br>25 Apr 2024<br>Technical check<br>Submission status Date<br>Submission is under technical check<br>25 Apr 2024<br>Submission passed technical check<br>26 Apr 2024<br>Editorial assignment<br>Submission status Date<br>Ready for editorial assignment<br>26 Apr 2024<br>With editor<br>Submission status Date<br>Editor assigned<br>26 Apr 2024<br>Peer review<br>Submission status Date<br>Submission under peer review<br>07 May 2024<br>Revision requested<br>18 Jun 2024<br>Revision received<br>26 Jun 2024<br>Submission passed technical check<br>27 Jun 2024<br>Submission accepted<br>Submission status Date<br>Submission accepted<br>18 Jul 2024<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>22 Jul 2024<br>Production<br>Submission status Date<br>Publishing and rights complete<br>23 Jul 2024<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf06405121, createdName=ms4000000387006148, createdTime=Tue Jul 23 09:56:04 CST 2024, time=2024-07-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向：糖尿病心肌病;药物治疗<br>经验分享：3.19投稿<br>4.14接收<br>5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京)]
    2024-07-23 ms4000000387006148 来自江苏省

    审稿速度:3.0 | 投稿命中率:75.0
    偏重的研究方向：糖尿病
    经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。

    Submission status Date
    Submission received
    25 Apr 2024
    Technical check
    Submission status Date
    Submission is under technical check
    25 Apr 2024
    Submission passed technical check
    26 Apr 2024
    Editorial assignment
    Submission status Date
    Ready for editorial assignment
    26 Apr 2024
    With editor
    Submission status Date
    Editor assigned
    26 Apr 2024
    Peer review
    Submission status Date
    Submission under peer review
    07 May 2024
    Revision requested
    18 Jun 2024
    Revision received
    26 Jun 2024
    Submission passed technical check
    27 Jun 2024
    Submission accepted
    Submission status Date
    Submission accepted
    18 Jul 2024
    Publishing and rights
    Submission status Date
    Submission is in publishing and rights
    22 Jul 2024
    Production
    Submission status Date
    Publishing and rights complete
    23 Jul 2024

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2269098, encodeId=ab4c22690984a, content=审稿速度:12.0 | 投稿命中率:75.0<br>偏重的研究方向：心衰和代谢<br>经验分享：投稿一共经历了10个月才接受，中间第一次审稿只找到一个审稿人，八个月才给意见，小修后又找了一个审稿人，再次小修，最后接收，一开始都不抱希望了，最后结果还是好的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c026408695, createdName=ms1000000018536500, createdTime=Thu Jun 12 22:19:31 CST 2025, time=2025-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2248527, encodeId=f623224852e05, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享：2024年7月投稿，到今天才给我1个审稿人的意见。中间催了3次啊，受不了了。重点是这个审稿人只是总结了我的文章，只提优点，没说缺点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0602318384, createdName=vgirlxin, createdTime=Fri Jan 17 20:29:55 CST 2025, time=2025-01-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：炎症;糖尿病;冠心病<br>经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2232367, encodeId=4c9f223236ebb, content=审稿速度:12.0 | 投稿命中率:50.0<br>偏重的研究方向：代谢综合征;糖尿病<br>经验分享：10月9号分配编辑，10月22依然Editor assigned，生死未卜, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1139312269, createdName=ms7000000399929724, createdTime=Tue Oct 22 10:48:41 CST 2024, time=2024-10-22, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2240719, encodeId=61512240e19e1, content=该期刊比较欢迎与糖尿病和代谢综合征相关的原创研究论文、综述、评论文章等<br>主要涵盖糖尿病及其相关代谢综合征的研究，包括临床研究、综述、评论等。因此，确保你的研究主题与该期刊的宗旨一致是非常重要的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822132, createdTime=Tue Dec 03 23:37:32 CST 2024, time=2024-12-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2216387, encodeId=cbd4221638eb4, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向：糖尿病<br>经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。<br><br>Submission status Date<br>Submission received<br>25 Apr 2024<br>Technical check<br>Submission status Date<br>Submission is under technical check<br>25 Apr 2024<br>Submission passed technical check<br>26 Apr 2024<br>Editorial assignment<br>Submission status Date<br>Ready for editorial assignment<br>26 Apr 2024<br>With editor<br>Submission status Date<br>Editor assigned<br>26 Apr 2024<br>Peer review<br>Submission status Date<br>Submission under peer review<br>07 May 2024<br>Revision requested<br>18 Jun 2024<br>Revision received<br>26 Jun 2024<br>Submission passed technical check<br>27 Jun 2024<br>Submission accepted<br>Submission status Date<br>Submission accepted<br>18 Jul 2024<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>22 Jul 2024<br>Production<br>Submission status Date<br>Publishing and rights complete<br>23 Jul 2024<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf06405121, createdName=ms4000000387006148, createdTime=Tue Jul 23 09:56:04 CST 2024, time=2024-07-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向：糖尿病心肌病;药物治疗<br>经验分享：3.19投稿<br>4.14接收<br>5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京)]
    2024-02-29 苦行僧难上加难 来自安大略

    昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？

    6

    展开6条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2269098, encodeId=ab4c22690984a, content=审稿速度:12.0 | 投稿命中率:75.0<br>偏重的研究方向：心衰和代谢<br>经验分享：投稿一共经历了10个月才接受，中间第一次审稿只找到一个审稿人，八个月才给意见，小修后又找了一个审稿人，再次小修，最后接收，一开始都不抱希望了，最后结果还是好的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c026408695, createdName=ms1000000018536500, createdTime=Thu Jun 12 22:19:31 CST 2025, time=2025-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2248527, encodeId=f623224852e05, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享：2024年7月投稿，到今天才给我1个审稿人的意见。中间催了3次啊，受不了了。重点是这个审稿人只是总结了我的文章，只提优点，没说缺点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0602318384, createdName=vgirlxin, createdTime=Fri Jan 17 20:29:55 CST 2025, time=2025-01-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：炎症;糖尿病;冠心病<br>经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2232367, encodeId=4c9f223236ebb, content=审稿速度:12.0 | 投稿命中率:50.0<br>偏重的研究方向：代谢综合征;糖尿病<br>经验分享：10月9号分配编辑，10月22依然Editor assigned，生死未卜, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1139312269, createdName=ms7000000399929724, createdTime=Tue Oct 22 10:48:41 CST 2024, time=2024-10-22, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2240719, encodeId=61512240e19e1, content=该期刊比较欢迎与糖尿病和代谢综合征相关的原创研究论文、综述、评论文章等<br>主要涵盖糖尿病及其相关代谢综合征的研究，包括临床研究、综述、评论等。因此，确保你的研究主题与该期刊的宗旨一致是非常重要的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822132, createdTime=Tue Dec 03 23:37:32 CST 2024, time=2024-12-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2216387, encodeId=cbd4221638eb4, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向：糖尿病<br>经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。<br><br>Submission status Date<br>Submission received<br>25 Apr 2024<br>Technical check<br>Submission status Date<br>Submission is under technical check<br>25 Apr 2024<br>Submission passed technical check<br>26 Apr 2024<br>Editorial assignment<br>Submission status Date<br>Ready for editorial assignment<br>26 Apr 2024<br>With editor<br>Submission status Date<br>Editor assigned<br>26 Apr 2024<br>Peer review<br>Submission status Date<br>Submission under peer review<br>07 May 2024<br>Revision requested<br>18 Jun 2024<br>Revision received<br>26 Jun 2024<br>Submission passed technical check<br>27 Jun 2024<br>Submission accepted<br>Submission status Date<br>Submission accepted<br>18 Jul 2024<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>22 Jul 2024<br>Production<br>Submission status Date<br>Publishing and rights complete<br>23 Jul 2024<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf06405121, createdName=ms4000000387006148, createdTime=Tue Jul 23 09:56:04 CST 2024, time=2024-07-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向：糖尿病心肌病;药物治疗<br>经验分享：3.19投稿<br>4.14接收<br>5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京)]
    2023-11-27 1df0083fm15(暂无匿称) 来自广东省

    审稿速度:2.0 | 投稿命中率:50.0
    经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。

    2

    展开2条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2269098, encodeId=ab4c22690984a, content=审稿速度:12.0 | 投稿命中率:75.0<br>偏重的研究方向：心衰和代谢<br>经验分享：投稿一共经历了10个月才接受，中间第一次审稿只找到一个审稿人，八个月才给意见，小修后又找了一个审稿人，再次小修，最后接收，一开始都不抱希望了，最后结果还是好的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c026408695, createdName=ms1000000018536500, createdTime=Thu Jun 12 22:19:31 CST 2025, time=2025-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2248527, encodeId=f623224852e05, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享：2024年7月投稿，到今天才给我1个审稿人的意见。中间催了3次啊，受不了了。重点是这个审稿人只是总结了我的文章，只提优点，没说缺点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0602318384, createdName=vgirlxin, createdTime=Fri Jan 17 20:29:55 CST 2025, time=2025-01-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：炎症;糖尿病;冠心病<br>经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2232367, encodeId=4c9f223236ebb, content=审稿速度:12.0 | 投稿命中率:50.0<br>偏重的研究方向：代谢综合征;糖尿病<br>经验分享：10月9号分配编辑，10月22依然Editor assigned，生死未卜, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1139312269, createdName=ms7000000399929724, createdTime=Tue Oct 22 10:48:41 CST 2024, time=2024-10-22, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2240719, encodeId=61512240e19e1, content=该期刊比较欢迎与糖尿病和代谢综合征相关的原创研究论文、综述、评论文章等<br>主要涵盖糖尿病及其相关代谢综合征的研究，包括临床研究、综述、评论等。因此，确保你的研究主题与该期刊的宗旨一致是非常重要的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822132, createdTime=Tue Dec 03 23:37:32 CST 2024, time=2024-12-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2216387, encodeId=cbd4221638eb4, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向：糖尿病<br>经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。<br><br>Submission status Date<br>Submission received<br>25 Apr 2024<br>Technical check<br>Submission status Date<br>Submission is under technical check<br>25 Apr 2024<br>Submission passed technical check<br>26 Apr 2024<br>Editorial assignment<br>Submission status Date<br>Ready for editorial assignment<br>26 Apr 2024<br>With editor<br>Submission status Date<br>Editor assigned<br>26 Apr 2024<br>Peer review<br>Submission status Date<br>Submission under peer review<br>07 May 2024<br>Revision requested<br>18 Jun 2024<br>Revision received<br>26 Jun 2024<br>Submission passed technical check<br>27 Jun 2024<br>Submission accepted<br>Submission status Date<br>Submission accepted<br>18 Jul 2024<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>22 Jul 2024<br>Production<br>Submission status Date<br>Publishing and rights complete<br>23 Jul 2024<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf06405121, createdName=ms4000000387006148, createdTime=Tue Jul 23 09:56:04 CST 2024, time=2024-07-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向：糖尿病心肌病;药物治疗<br>经验分享：3.19投稿<br>4.14接收<br>5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京)]
    2023-05-06 zwwandzl 来自北京

    审稿速度:2.0 | 投稿命中率:95.0
    偏重的研究方向：糖尿病心肌病;药物治疗
    经验分享：3.19投稿
    4.14接收
    5.6online

    3

    展开3条回复
共70条页码: 1/7页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分